Graham Price

P-69. What if? Opportunities for IV to PO Antibiotic Transition in Bone and Joint Infection Treatment

Graham Price, Makeisha Dance, Patrick Jackson, Corey J. Medler

Abstract Background Historically, bone and joint infections have been treated with intravenous (IV) antimicrobials. IV to oral (PO) antibiotic transition implementation differs among institutions and prescribers. This practice has increased in recent years as new literature has demonstrated comparable efficacy of PO …

us (code pays fourni par la source)

Curriculum mapping of accredited pharmacy programs in the United States

Azita H. Talasaz, Krista L. Donohoe, Benjamin W. Van Tassell, Albert M. Truong et autres

us (code pays fourni par la source)

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Peter C. Kiessling, Rocío Lledó‐García, Shikiko Watanabe, Grant Langdon et autres

= 1)]. Rozanolixizumab pharmacokinetics demonstrated nonlinear increases with dose. There were sustained dose-dependent reductions in serum IgG concentrations (IV and SC rozanolixizumab). These data provide clinical evidence for the therapeutic potential of rozanolixizumab.

de, gb, be (code pays fourni par la source)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Sophie Glatt, Eric Helmer, Birgit Haier, Foteini Strimenopoulou et autres

AIMS: To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL)-17A and IL-17F, in subjects with mild plaque psoriasis. METHODS: Randomized, double-blind, first-in-human study of bimekizumab in 39 subjects …

gb, de (code pays fourni par la source)

Abstract 193: Lapaquistat Acetate, A Novel Squalene Synthase Inhibitor, Co-administered with Atorvastatin Reduces Plasma Lipids and C-Reactive Protein Levels in Subjects with Primary Hypercholesterolemia

Michael H. Davidson, Kevin Carl Maki, James H. Zavoral, Shawn S. Yu et autres

Background/Objective: Lapaquistat acetate (LAPA), a novel lipid-lowering agent, inhibits squalene synthase, an enzyme distal to HMG-CoA reductase in the cholesterol biosynthetic pathway. We evaluated the effects of LAPA on LDL-C, other plasma lipid variables, and high-sensitivity C-reactive protein (hs-CRP) levels when co-administered …

us, gb (code pays fourni par la source)

Abstract 1493: TAK-475, a Squalene Synthase Inhibitor, Improves Lipid Profile in Hyperlipidemic Subjects

Ed Piper, Graham Price, Yinzhong Chen

TAK-475 decreases LDL-C by inhibiting squalene synthase; this contrasts with statins, which act on HMG-CoA reductase. Preliminary data showed that TAK-475 is safe and improves lipid profiles in ani...